Quectel Announces New Generation 5G Release 17 Module Series to Address Growing 5G FWA and eMBB Markets
27.2.2023 10:00:00 EET | Business Wire | Press release
MWC BARCELONA – Quectel Wireless Solutions, a global IoT solutions provider, today announces the launch of its latest generation 5G New Radio (NR) module series, the RG650E and RG650V, both of which follow the 3GPP Release 17 standard. These industrial grade 5G modules deliver enhanced performance in data rates, capacity, power saving, and latency as well as ultra-reliability, better addressing the growing 5G fixed wireless access (FWA), enhanced mobile broadband (eMBB), and industrial automation markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230226005190/en/
Quectel announces new generation 5G Release 17 module series to address growing 5G FWA and eMBB markets (Photo: Business Wire)
Based on the latest Snapdragon® X75 and X72 5G Modem-RF Systems from Qualcomm Technologies, Inc., the RG650E and RG650V series can work on both 5G non-standalone (NSA) and standalone (SA) modes. The RG650E supports a maximum bandwidth of 300 MHz in the sub-6GHz spectrum while the RG650V supports up to 200 MHz bandwidth. The adoption of Option 3x/ 3a/ 3 and Option 2 network architectures makes the modules backward compatible with global LTE and WCDMA networks.
Quectel also provides an RG650x-based System-on-Chip (SoC) solution with the latest Wi-Fi 7 technology, which significantly increases transfer speeds, reduces latency, and boosts overall network capacity for customer applications. Additionally, the module’s support of OpenWRT allows it to provide advanced networking features in a wider range of upstream ecosystem applications.
Integrated with a Quad-Core A55 processor, the RG650E and RG650V support 5G NR downlink carrier aggregation (CA), greatly improving data rates to meet the demand for super high data speeds in IoT verticals and applications, especially for FWA devices like CPE, home gateway, enterprise gateway, industrial router, mobile hotspot, eMBB terminals including high-definition live broadcast, AR/VR device, drone as well as industrial automation applications such as automated guided vehicles (AGV), remote control, and robot.
“We are excited to roll out the industry’s most advanced 5G NR modules based on the cutting-edge Snapdragon X75 and X72,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Our latest 5G NR Release 17 modules feature unprecedented performance and significant advantages in communication capability. I believe they will provide an excellent Sub-6GHz, mmWave and Wi-Fi 7 solution for the growing 5G FWA and eMBB markets.”
“Snapdragon X75 and X72, the world’s first 5G Advanced-ready modem-RF system provides unparalleled features and capabilities for performance, power efficiency, and flexibility making it the ideal solution for various highly demanding applications and use cases,” said Gautam Sheoran, vice president, product management, Qualcomm Technologies, Inc. “We are excited to see Quectel adopting our new modem-RF systems to drive the next stage of 5G evolution in all key verticals including FWA, home getaways, Industrial IoT, and more.”
The RG650E and RG650V series supports Qualcomm® Location Suite with Qualcomm® GNSS HW Gen 9.v6 (Concurrent GPS, BeiDou, Galileo, GLONASS, NavIC, and QZSS). The integrated GNSS receiver greatly simplifies product design and provides quicker, more accurate, and more dependable positioning capability for applications in any environment. Additionally, they provide a wide range of interfaces such as USXGMII, PCIe, USB 2.0/ 3.0/ 3.1, PCM and supplementary functions including VoLTE and VoNR.
The Quectel 5G module offering is complemented by its range of antennas which help optimize connection efficiency and aid ease of installation of devices. These can be supplied pre-integrated with Quectel IoT modules to accelerate time to market and help eliminate commonly found integration issues.
Engineering samples of the RG650E and RG650V will be available for global markets in the first half of 2023. To learn more, visit the Quectel booth at MWC Barcelona 2023, Hall 5, Booth 5A20.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Snapdragon and Qualcomm are trademarks or register trademarks of Qualcomm Incorporated.
Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005190/en/
Contact information
Media:
Phil Rawcliffe, Head of Communications
phil.rawcliffe@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
